000130774 001__ 130774
000130774 005__ 20240228145552.0
000130774 0247_ $$2doi$$a10.1093/jnci/djx034
000130774 0247_ $$2pmid$$apmid:28383653
000130774 0247_ $$2ISSN$$a0027-8874
000130774 0247_ $$2ISSN$$a0198-0157
000130774 0247_ $$2ISSN$$a1460-2105
000130774 0247_ $$2altmetric$$aaltmetric:18582437
000130774 037__ $$aDKFZ-2017-05852
000130774 041__ $$aeng
000130774 082__ $$a610
000130774 1001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b0$$eFirst author$$udkfz
000130774 245__ $$aImmune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
000130774 260__ $$aOxford$$bOxford Univ. Press$$c2017
000130774 3367_ $$2DRIVER$$aarticle
000130774 3367_ $$2DataCite$$aOutput Types/Journal article
000130774 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663661030_25469$$xReview Article
000130774 3367_ $$2BibTeX$$aARTICLE
000130774 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130774 3367_ $$00$$2EndNote$$aJournal Article
000130774 500__ $$aVolume 109, Issue 10, October 2017, djx034
000130774 520__ $$aCurrent therapies against cancer utilize the patient's immune system for tumor eradication. However, tumor cells can evade immune surveillance of CD8+ T and/or natural killer (NK) cells by various strategies. These include the aberrant expression of human leukocyte antigen (HLA) class I antigens, co-inhibitory or costimulatory molecules, and components of the interferon (IFN) signal transduction pathway. In addition, alterations of the tumor microenvironment could interfere with efficient antitumor immune responses by downregulating or inhibiting the frequency and/or functional activity of immune effector cells and professional antigen-presenting cells. Recently, microRNAs (miRNAs) have been identified as major players in the post-transcriptional regulation of gene expression, thereby controlling many physiological and also pathophysiological processes including neoplastic transformation. Indeed, the cellular miRNA expression pattern is frequently altered in many tumors of distinct origin, demonstrating the tumor suppressive or oncogenic potential of miRNAs. Furthermore, there is increasing evidence that miRNAs could also influence antitumor immune responses by affecting the expression of immune modulatory molecules in tumor and immune cells. Apart from their important role in tumor immune escape and altered tumor-host interaction, immune modulatory miRNAs often exert neoplastic properties, thus representing promising targets for future combined immunotherapy approaches. This review focuses on the characterization of miRNAs involved in the regulation of immune surveillance or immune escape of tumors and their potential use as diagnostic and prognostic biomarkers or as therapeutic targets.
000130774 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130774 588__ $$aDataset connected to CrossRef, PubMed,
000130774 650_7 $$2NLM Chemicals$$aB7 Antigens
000130774 650_7 $$2NLM Chemicals$$aHLA Antigens
000130774 650_7 $$2NLM Chemicals$$aHLA-G Antigens
000130774 650_7 $$2NLM Chemicals$$aMicroRNAs
000130774 650_7 $$082115-62-6$$2NLM Chemicals$$aInterferon-gamma
000130774 7001_ $$0P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aOsen, Wolfram$$b1$$udkfz
000130774 7001_ $$aMandelboim, Ofer$$b2
000130774 7001_ $$aSeliger, Barbara$$b3
000130774 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djx034$$gVol. 109, no. 10$$n10$$pdjx034$$tJournal of the National Cancer Institute$$v109$$x1460-2105$$y2017
000130774 909CO $$ooai:inrepo02.dkfz.de:130774$$pVDB
000130774 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130774 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130774 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130774 9141_ $$y2017
000130774 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000130774 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130774 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2015
000130774 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130774 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130774 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130774 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130774 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130774 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130774 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130774 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130774 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130774 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130774 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130774 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130774 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2015
000130774 9201_ $$0I:(DE-He78)G182-20160331$$kG182$$lGMP Einheit  Zelluläre Therapie$$x0
000130774 980__ $$ajournal
000130774 980__ $$aVDB
000130774 980__ $$aI:(DE-He78)G182-20160331
000130774 980__ $$aUNRESTRICTED